TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2503289
Drug: IVF without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVF without daily exercise
Study: 31030165
Drug: Pinitol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinitol (300 mg/d)
Study: 31030165
Drug: Pinitol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinitol (500 mg/d)
Study: 25876832
Drug: CR nifedipine
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR nifedipine (80 mg per day; 40 mg BID)
Study: 25885986
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 300 mcg
Study: 25885986
Drug: Oral metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoprolol 50 mg
Study: 17225162
Drug: AZD3480 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 (50 mg, 100 mg, 200 mg)
Study: 17225162
Drug: AZD3480 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 (single dose from 2 to 320 mg)
Study: 17225162
Drug: AZD3480 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 (50 mg, 200 mg)
Study: 17225162
Drug: AZD3480 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 (200 mg)
Study: 11472614
Drug: GM‐CSF impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF impregnated gauze (40 micrcog/cm2 of skin‐irradiated area, twice per day) in addition to steroid cream
Study: 11472614
Drug: Steroid cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid cream
Study: 3126635
Drug: Deponit 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deponit 10 patch (10 mg of nitroglycerin over 24 hours)
Study: 3126635
Drug: Deponit 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deponit 10 patch
Study: 27602880
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) consisting of 12 individual 1-hour sessions administered weekly by trained clinicians
Study: 19907724
Drug: Hydroxyapatite (HA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite (HA) treatment
Study: 15864232
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy during index hospitalization
Study: 15864232
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering therapy during index hospitalization
Study: 15864232
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with prior history of hyperlipidemia not discharged on lipid-lowering therapy
Study: 15864232
Drug: Inpatient lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient lipid-lowering therapy
Study: 14578647
Drug: Chemotherapy agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy agents (e.g., fluorouracil, gemcitabine, taxanes, capecitabine)
Study: 11275925
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abciximab and reduced-dose thrombolytic agent) with adjunctive PCI
Study: 11275925
Drug: Full-dose thrombolytic
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose thrombolytic agent alone with adjunctive PCI
Study: 11275925
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abciximab) with adjunctive PCI
Study: 11275925
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abciximab) without adjunctive PCI
Study: 11275925
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy alone with adjunctive PCI
Study: 11275925
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy alone without adjunctive PCI
Study: 9249638
Drug: Polylactic-acid-based bioabsorbable
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polylactic-acid-based bioabsorbable barrier (test treatment)
Study: 9249638
Drug: Non-absorbable ePTFE
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-absorbable ePTFE barrier (control treatment)
Study: 21070344
Drug: Programme-assessed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programme-assessed treatment (elaborate feedback)
Study: 21070344
Drug: Student-assessed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Student-assessed treatment (minimal feedback)
Study: 16761129
Drug: d,l-methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-methamphetamine
Study: 14586363
Drug: Desmopressin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.1 mg, 0.2 mg, or 0.4 mg)
Study: 8937366
Drug: Penthienate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penthienate (5 mg, three times a day for 4 weeks)
Study: 8937366
Drug: Propantheline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline (15 mg, three times a day for 4 weeks)
Study: 24688087
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m²)
Study: 8590507
Drug: Diazepam 0.4
Normalized name: diazepam 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.4 mg.kg‐1
Study: 8311533
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with steroids
Study: 22341744
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care
Study: 16942452
Drug: Mime therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mime therapy for three months (including massage, relaxation, inhibition of synkinesis, and coordination and emotional expression exercises)
Study: 16942452
Drug: Mime therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mime therapy for three months
Study: 10735462
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion with albumin 20% 15 ml/kg
Study: 1392423
Drug: Intravenous ANF(99‐126)
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ANF(99‐126) (bolus 100 micrograms/kg, 30‐min infusion of 0.1 micrograms/kg.min)
Study: 1392423
Drug: Combined releasing
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined releasing hormone administration
Study: 3904233
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily for 2 years
Study: 2858709
Drug: Untreated control
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated control group with systemic therapy reserved until the time of relapse
Study: 17167974
Drug: Splenectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splenectomy without immunotherapy (OK-432 administration)
Study: 17167974
Drug: Splenectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splenectomy with immunotherapy
Study: 17167974
Drug: Spleen preservation
Normalized name: Bos taurus spleen preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen preservation without immunotherapy
Study: 17167974
Drug: Spleen preservation
Normalized name: Bos taurus spleen preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spleen preservation with immunotherapy
Study: 12860257
Drug: CETi‐1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETi‐1 vaccine (250 mg)
Study: 12860257
Drug: CETi‐1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETi‐1 vaccine (second injection)
Study: 12860257
Drug: CETi‐1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETi‐1 vaccine
Study: 9350242
Drug: MMC +
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC + HCFU (intravenous MMC 6 mg/m2 on the day of operation followed by oral HCFU for 12 months from 2 weeks after operation)
Study: 8478958
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of ethanol (approximately two average drinks) per day for three menstrual cycles
Study: 3533551
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of controlled release theophylline (Uniphyllin)
Study: 3533551
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of controlled release theophylline (Uniphyllin)
Study: 3533551
Drug: Control (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (morning vs evening administration)
Study: 26251065
Drug: Work-focused cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-focused cognitive-behavioural therapy (CBT) and individual job support
Study: 23290982
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of zoledronate 5 mg
Study: 21303636
Drug: Differentiated SoloSTAR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differentiated SoloSTAR® pens (insulin glargine vs insulin glulisine)
Study: 21303636
Drug: FlexPen® (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FlexPen® (insulin detemir vs insulin aspart)
Study: 19577022
Drug: Sham (placebo)
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (placebo) treatment 2 hours/day for 3 months
Study: 16455169
Drug: Third-generation hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation hepatitis B vaccine containing PreS1 and PreS2 antigens in addition to the S antigen
Study: 16455169
Drug: Conventional hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hepatitis B vaccine
Study: 11704163
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of metronidazole gel intravaginally
Study: 3126085
Drug: Superselective intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Superselective intra-arterial chemotherapy with mitomycin C (SIAC)
Study: 3126085
Drug: Chemotherapy toxicity
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy toxicity after SIAC
Study: 19001531
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (intervention group)
Study: 25748415
Drug: Amoxicillin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (two 500 mg tablets three times a day for 7 days)
Study: 24160442
Drug: Systematic CVD
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic CVD risk reduction package including healthy lifestyle counseling, prescription of a combination of drugs (antihypertensives, aspirin, and statin), and adherence support.
Study: 1303480
Drug: Propofol 2.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.04 mg/kg
Study: 1303480
Drug: Methohexitone 1.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone 1.05 mg/kg
Study: 6099756
Drug: Cefotaxime (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (multiple doses)
Study: 14675576
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus simvastatin (10, 20, 40, or 80 mg)
Study: 14675576
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy (10, 20, 40, or 80 mg)
Study: 11170979
Drug: Potent antiretroviral
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent antiretroviral therapy including ritonavir and saquinavir
Study: 3202339
Drug: Spinal anaesthetic
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthetic with 1.5 mg.kg‐1 prilocaine (RA)
Study: 3202339
Drug: General anaesthetic
Normalized name: General anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthetic with 5 mg.kg‐1 thiopentone, dextromoramide, nitrous oxide and enflurane (GA)
Study: 30175930
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg plus chlorthalidone
Study: 30175930
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 80 mg plus chlorthalidone
Study: 24447649
Drug: Rasagiline 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 6 mg/day
Study: 1584429
Drug: Selegiline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline monotherapy
Study: 1750727
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg b.i.d.
Study: 1750727
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg b.i.d.
Study: 6751366
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline 350 mg daily for 4 days followed by 700 mg daily for 4 days
Study: 6751366
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for 8 days
Study: 30509740
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks intravenously
Study: 29282470
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (10 daily 30-minute, 2-mA sessions)
Study: 26740484
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen therapy
Study: 24488324
Drug: Icotinib 400
Normalized name: inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib 400 mg with high-fat and high-calorie meal
Study: 24488324
Drug: Icotinib (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (dose range 100-600 mg)
Study: 22156624
Drug: EP/XRT (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP/XRT (cisplatin and etoposide with concurrent chest radiation)
Study: 11986603
Drug: Non-heparin-bonded circuits
Normalized name: SKIN BOND NON-FLAMMABLE CEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-bonded circuits with cardiotomy suction (group I)
Study: 11986603
Drug: Heparin-bonded circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded circuits with cardiotomy suction (group II)
Study: 11986603
Drug: Heparin-bonded circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded circuits without cardiotomy suction (group III)
Study: 9706319
Drug: Social-cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-cognitive group intervention (ten, 2-hour weekly sessions)
Study: 9706319
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of drug/alcohol users and nonusers, fighters and nonfighters, and students threatened at school and those not threatened
Study: 7618676
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg by bolus injection followed by infusion (5 mg.h‐1 for 12 h and 2.5 mg.h‐1 for a further 12 h)
Study: 7618676
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg by bolus injection followed by infusion (10 mg.h‐1 for 12 h and 5 mg.h‐1 for a further 12 h)
Study: 7618676
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate 2 mg by bolus injection followed by infusion (0.2 mg.h‐1 for 12 h and at 0.1 mg.h‐1 for further 12 h)
Study: 28750828
Drug: Alirocumab (75/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75/150 mg every 2 weeks)
Study: 26712972
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg (Group O, n = 32)
Study: 26712972
Drug: glycopyrrolate 0.2
Normalized name: glycopyrrolate 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate 0.2 mg (Group G, n = 31)
Study: 11339442
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg folic acid daily
Study: 11339442
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg folic acid daily
Study: 9148986
Drug: Diagnostic peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic peritoneal lavage (DPL) with 1 L crystalloid
Study: 8131364
Drug: Natural surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural surfactant extract (prophylactic administration)
Study: 8131364
Drug: Natural surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural surfactant extract (administration to infants with moderate to severe RDS)
Study: 31352308
Drug: High-risk drug
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk drug use (methamphetamine, cocaine, opioids)
Study: 26741306
Drug: Anterior mini-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior mini-implant group (AMG)
Study: 26741306
Drug: Posterior mini-implant
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior mini-implant group (PMG)
Study: 22527337
Drug: Cement injection
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cement injection stem (secondary cementing technique)
Study: 19326803
Drug: Multidisciplinary quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary quality improvement program to reduce RFOs, including education programs, team training, simulation videos, and daily reminders.
Study: 11075845
Drug: Intranasal civamide
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal civamide 20 microg
Study: 11075845
Drug: Intranasal civamide
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal civamide 150 microg
Study: 3732891
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (total parenteral nutrition and steroids)
Study: 31780130
Drug: iCBT (internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-delivered cognitive behavioural therapy)
Study: 16291600
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg etoricoxib once daily
Study: 16291600
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg rofecoxib once daily
Study: 3710013
Drug: Sucrose diet
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose diet (45 g of sucrose replacing 45 g of complex carbohydrate)
Study: 29803703
Drug: ALPS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALPS treatment group
Study: 17318503
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg daily
Study: 24359506
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg daily
Study: 22260988
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (one, two, or three doses at 1 month, 2 months, or 6 months intervals)
Study: 22260988
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (two or three doses)
Study: 22260988
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (second or third doses)
Study: 24699554
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection
Study: 24699554
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: 17904629
Drug: Treatment (phone-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (phone- and mail-based physical activity maintenance intervention)
Study: 12534644
Drug: Erythromycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (600 mg ethylsuccinate ester, three oral doses on day 1 and two doses on day 2)
Study: 3883182
Drug: Omeprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (30 mg per day)
Study: 20215456
Drug: Intensive glycemia
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemia treatment
Study: 25082605
Drug: Intervention (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (monthly telephone interviews for six months)
Study: 11257953
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg every 8 h
Study: 11257953
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg every 8 h
Study: 3346792
Drug: Metoclopramide (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.125 mg/kg intravenous dose)
Study: 3346792
Drug: Metoclopramide (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.125 mg/kg four times a day for 24 hours)
Study: 29769088
Drug: Randomisation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomisation to one of two comparable drugs during a routine consultation
Study: 29769088
Drug: Electronic system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic system randomising a patient to drug A or drug B